Long-term Outcomes of Critical Illness Survivors

Sponsor
Jian-jun Yang (Other)
Overall Status
Unknown status
CT.gov ID
NCT03940755
Collaborator
(none)
200
2
25
100
4

Study Details

Study Description

Brief Summary

The goal of this study is to assess the Long-term Outcomes of Critical Illness Survivors,including physical, psychological, and cognitive sequelae.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    An increasing number of patients survive critical illness; however, the evidence reveals that over the same period the number of patients being sent to rehabilitation settings have tripled . For those who do survive, the latest data indicate that 50-70% of ICU "survivors" will suffer cognitive impairment and 60-80% of "survivors" will suffer functional impairment or ICU-acquired weakness (ICU-AW).Still,there is a lack valid data on the long-term impact on morbidity from prospective observational studies. Therefore, the investigators designed an observational cohort which cover a broader range of outcomes to quantify long-term physical, psychological, and cognitive impairment after intensive care unit (ICU).Intensive Care Unit patients survive from critical illness will be approached for study recruitment and participation.Survival rate,Quality of life,Cognitive impairments,Depression and anxiety,PTSD,Physical activity,Neuromuscular impairment will be assessed 3 or 6 months after ICU discharge.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    200 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Long-term Outcomes of Critical Illness Survivors:a Prospective Cohort Study
    Actual Study Start Date :
    Jun 1, 2019
    Anticipated Primary Completion Date :
    Oct 1, 2020
    Anticipated Study Completion Date :
    Jun 30, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    Critical Illness Survivors

    Those intensive care unit(ICU) patients who survive from critical illness.

    Outcome Measures

    Primary Outcome Measures

    1. Survival rate of ICU survivors [3 or 6 months after ICU discharge]

      Critically ill patients discharged from ICU are defined as survivors

    Secondary Outcome Measures

    1. Assessment of life quality [3 or 6 months after ICU discharge]

      Quality of Life assessed with help of The 36-item short from health survey(SF-36)questionnaire.The SF-36 has 8 scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0-100. Lower scores = more disability, higher scores = less disability.The 8 sections are listed below:PF:Physical Functioning,RP:Role-Physical,BP:Bodily Pain,GH:General Health,VT:Vitality,SF:Social Functioning,RE:Role-Emotional,MH:Mental Health.

    2. Assessment in Physical dysfunction [3 or 6 months after ICU discharge]

      Functional disabilities assessed with help of Barthel index of ADL(activities of daily living).10 variables are addressed. Range of summed total score: 0-100. higher values represent better outcome.

    3. Assessment in depression and anxiety [3 or 6 months after ICU discharge]

      Depression and anxiety assessed with help of The Hospital Anxiety and Depression Scale(HADS).For Depression(D), 7 questions in total. Range of score for each question: 0-3. Total score summed: 0-21 ;For Anxiety(A): 7 questions in total. Range of score for each question: 0-3. Total score summed: 0-21 .For both D and A scales, higher scores represent worse outcome.

    4. Assessment in PTSD [3 or 6 months after ICU discharge]

      Post-traumatic stress syndrome assessed with help of trauma screening questionnaire(TSQ).There are 10 questions in the TSQ. For each question, the answer is either YES or NO. More YES = worse outcome. At least 6 YES represents PTSD diagnosis.

    5. Assessment in Cognitive impairments [3 or 6 months after ICU discharge]

      Cognitive impairments assessed with help of mini-mental state examination(MMSE).The MMSE has 5 scaled scores; the scores are weighted sums of the questions in each section. The 5 sections and their range of score are listed below:Orientation 0-10;Registration 0-3;Attention and calculation 0-5;Recall 0-3;Language 0-9.Total score range from 0-30. Lower scores = more disability, higher scores = less disability.

    6. Patients' care and support needs;social and economical consequences [3 or 6 months after ICU discharge]

      Patients' information of specific needs and supports and social or economical impact post ICU.

    7. Neuromuscular impairment [3 or 6 months after ICU discharge]

      Neuromuscular impairment will be assessed by electromyography/nerve conduction study

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients aged >17 years

    • Patients in intensive care unit(ICU) with at least one organ or system dysfunction,such as respiratory failure, cardiogenic shock,or septic shock.

    Exclusion Criteria:
    • Refuse to participate

    • Death before ICU discharge

    • pre-existing cognitive impairment, malignant tumor

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Jiangyin People's Hospital Jiangyin Jiangsu China 210009
    2 Zhongda Hospital Nanjing Jiangsu China 210009

    Sponsors and Collaborators

    • Jian-jun Yang

    Investigators

    • Principal Investigator: Jian-jun Yang, PhD, Zhongda Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Jian-jun Yang, Director,Department of Anesthesiology, Zhongda Hospital
    ClinicalTrials.gov Identifier:
    NCT03940755
    Other Study ID Numbers:
    • 20190501
    First Posted:
    May 7, 2019
    Last Update Posted:
    Jan 7, 2020
    Last Verified:
    Jan 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 7, 2020